Best Life Sciences Companies in Gelderland, Netherlands
The 83 best Life Sciences companies in Gelderland, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Xenikos.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Gelderland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Xenikos Developer of toxin-loaded antibodies for T-cell mediated diseases | $82M | 44 mo ago | Series C | 17 | — | 6 patents Targeted immunotoxin therapeutics for cancer treatment | — |
| 2 | Tagworks Pharmaceuticals Developer of antibody-drug-conjugates for cancer treatment | $65M | 36 mo ago | Series A | 13 | Zach Taylor Co-Founder | 144 patents Bioorthogonal click chemistry reagents for targeted drug/protein delivery and release | — |
| 3 | Esperite Cord blood Bank | $49M | 70 mo ago | Late Stage | 72 | — | — | — |
| 4 | TIBEAY Biosciences Clinical-stage biopharmaceutical company focused on developing innovative therapies for acute neurological… | $41M | 2 mo ago | Series C | — | Klaas Boer Co-Founder | — | — |
| 5 | ScreenPoint Developer of artificial intelligence software for analyzing breast imaging mammograms | $33M | 2 mo ago | Series C | 58 | Michael Brady Co-Founder & Chairman | — | — |
| 6 | InteRNA Technologies Discovering and developing microRNA (miRNA)-based therapeutics for oncology | $33M | 64 mo ago | Deadpooled | 13 | — | 20 patents Patents concentrated in chemistry & materials | — |
| 7 | Nutrileads Developer of nutritional ingredients with demonstrated health effects | $13M | 30 mo ago | Series C | 17 | — | 73 patents Patents concentrated in health & consumer products | — |
| 8 | Enzyre Developer of smart diagnostics devices for blood coagulation analysis | $12M | 43 mo ago | Series A | 20 | — | 23 patents Patents concentrated in transport & manufacturing processes | — |
| 9 | Alveron Pharma Developer of drugs to treat haemorrhagic stroke or intracranial haemorrhage | $12M | 56 mo ago | Series A | 3 | — | 8 patents Cyclodextrin-based procoagulant formulations for hemostatic drug delivery | — |
| 10 | GATT Technologies BV Polymer-based General Adhesive Tissue Tape | $11M | 60 mo ago | Series B | 22 | Johan Bender Founder | — | — |
| 11 | CardiacBooster Provider of percutaneous left ventricular assist devices | $11M | 10 mo ago | Funding Raised | 18 | — | 42 patents Mechanical circulatory support devices—axial-flow and high-frequency cardiac assist pumps. | — |
| 12 | Mellon Medical A suturing device with only one hand needed to operate the device | $7M | 104 mo ago | Series B | 6 | — | 53 patents Innovative needle‑suture combos and coupling mechanisms for surgical suturing devices | — |
| 13 | Hudson River Biotechnology Developer of DNA-free CRISPR technology for crop resilience and yield improvement | $6M | 26 mo ago | Series A | 30 | — | 4 patents Encapsulation particles for delivering hydrophilic/amphiphilic bio‑compounds | — |
| 14 | Khondrion Small molecule therapeutics for mitochondrial diseases | $4M | 19 mo ago | Seed | — | Jan Smeitink Founder & CEO | 92 patents Small-molecule therapeutics for mitochondrial disease and MPGES‑1‑mediated neuroinflammation | — |
| 15 | PulseCath Developer of circulatory support systems for use in patients with heart failure | $3M | 57 mo ago | Series A | 17 | Yoram Karmon CEO & President | 24 patents Catheter-based blood pump and valve technologies for circulatory support devices | — |
| 16 | ArthroSave Developer of knee support for osteoarthritis surgical treatment | $3M | 41 mo ago | Series B | 7 | Peter Roermund Co-Founder & CMO | 3 patents Orthopedic bone fixation and distraction devices for surgical implant connections. | — |
| 17 | QurieGen AI-powered drug discovery platform for cancer treatment | $2M | 14 mo ago | Seed | — | Kinga Matula Founder & CEO | — | 1 partnership |
| 18 | MindAffect Manufacturer and developer of industrial robots | $2M | 25 mo ago | Series A | 10 | Ivo Box Co-Founder & CEO | 10 patents Assessing individual sensory function using bioelectrical electrode sensing and data analysis | — |
| 19 | ATRO Medical Developer of a polymer-based meniscus implant | $2M | 3 mo ago | Series A | 9 | Tony Tienen CEO & CMO | 23 patents Flexible meniscus prostheses for knee and stifle joint replacement and stabilization | — |
| 20 | Aiosyn AI-based disease diagnosis tool for providers | $2M | 9 mo ago | Series A | 15 | Jeroen der Laak Co-Founder | — | — |
| 21 | Bio-Prodict Developer of a bioinformatics computational platform for the analysis of biological data | $2M | 60 mo ago | Funding Raised | — | Henk-Jan Joosten CEO & Owner | — | — |
| 22 | Scope Biosciences Developer of CRISPR-Cas based diagnostic platform | $2M | 31 mo ago | Seed | 8 | Stijn Prinsen Co-Founder | 4 patents Type III CRISPR/Cas molecular diagnostic assays for nucleic acid detection | — |
| 23 | Future Diagnostics Manufacturer of in-vitro diagnostic assay | $933K | 113 mo ago | Funding Raised | 64 | — | 27 patents Immunoassay kits and reagents for measuring free 25‑hydroxy vitamin D in blood. | — |
| 24 | Innosieve Diagnostics Provider of microbial diagnostic test kits | $769K | 62 mo ago | Funding Raised | 3 | — | 5 patents Microfilter centrifuge tubes for enhanced sample filtration and separation in laboratory diagnostics | — |
| 25 | TROPIQ Health Sciences Barcoded live insect screening technology | $464K | 52 mo ago | Funding Raised | 15 | Koen Dechering Cofounder and VP of business development | 16 patents Patents concentrated in health & consumer products | — |
| 26 | NovioSense In the eye connected continuous glucose monitor for diabetes | $309K | 115 mo ago | Series A | 3 | — | 17 patents Implantable medical device coatings and biosensor fabrication for biomedical monitoring. | — |
Top 12 Life Sciences companies in Gelderland
#1
Series C · Nijmegen, Gelderland · founded 2014 · 58 employees$33Mraised▾
Developer of artificial intelligence software for analyzing breast imaging mammograms. This technology integrates with existing medical imaging hardware to assist radiologists in detecting cancer. The software provides automated analysis of breast density and compares current images against previous examinations to identify potential abnormalities. It functions across various imaging systems to support clinical workflows in diagnostic environments.
- Apr 2026Series C$14M
- Apr 2026Grant (prize money)$2M
- Jul 2021Series C$28M
- May 2018Series B$5M
#2
Series C · Nijmegen, Gelderland · founded 2025$41.2Mraised▾
Clinical-stage biopharmaceutical company focused on developing innovative therapies for acute neurological conditions. The company focuses on developing therapies for acute neurological conditions. Its lead compound, Ronopterin, a selective iNOS inhibitor, for severe traumatic brain injury. It aims to reduce secondary brain injury, a condition with no approved pharmacological treatment.
- Apr 2026Series C$41.2M
#3
Series A · Nijmegen, Gelderland · founded 2016 · 9 employees$2.1Mraised▾
Developer of a polymer-based meniscus implant. The company has developed Trammpolin, a synthetic, non-resorbable anatomically shaped polymer-based meniscus implant for restoring the protective function of the meniscus by acting as a joint spacer. It reduces pain and restores mobility.
- Feb 2026Series A$3.5M
- Jan 2022Grant (prize money)$2.7M
- Dec 2021Series A$2.1M
- 2018Series A—
#4
Funding Raised · Nijmegen, Gelderland · founded 2018 · 18 employees$10.8Mraised▾
CardiacBooster provides percutaneous left ventricular assist devices. The company's devices are used to support the cardiac function of hemodynamically unstable patients. The device focus on ventricular support, cardiogenic shock, and high-risk PCI.
- Aug 2025Grant (prize money)$10.8M
- Dec 2019Grant (prize money)—
- Nov 2018Conventional Debt—
#5
Series A · Nijmegen, Gelderland · founded 2021 · 15 employees$2.1Mraised▾
AI-based disease diagnosis tool for providers. The company has developed software that assists with clinical disease diagnosis. It has features for breast and prostate cancer diagnostics, computational pathology, disease diagnosis, and more.
- Sep 2025Series A$2.8M
- Dec 2022Seed$2.1M
- Feb 2022Seed—
#6
Seed · Nijmegen, Gelderland · founded 2010$4Mraised▾
Khondrion focused on developing small molecule therapeutics for mitochondrial diseases. Its lead candidate KH176 is an orally bio-available small molecule being developed for the treatment of MELAS syndrome and other mitochondrial respiratory chain/OXPHOS diseases (Phase 1). KH176 is a member of a class of drugs essential for the control of oxidative and redox pathologies. Both European Commission and US- FDA has granted KH176 an orphan drug designation for all inherited mitochondrial respiratory chain disorders. The company also has a strategic partnership with the Nijmegen Centre for Mitochondrial Disorders of the Radboud University Medical Centre, Nijmegen. The company is supported by the Dutch Foundations Energy4All, Join4Energy, Ride4Kids, Road4Energy, Tim Foundation, Zeldzame Ziekten Fonds, the Prinses Beatrix Fonds, and National (NWO, ALW, ZonMW) and European Governments (Marie-Curie ITN, Eurostars).
- Nov 2024Seed—
- Nov 2022Grant (prize money)$270.8K
- Sep 2021Grant (prize money)$58.2K
- Oct 2018Grant (prize money)$2.7M
#7
Seed · Nijmegen, Gelderland · founded 2022$2.4Mraised▾
AI-powered drug discovery platform for cancer treatment. The company utilizes a high-throughput proprietary approach for mapping cellular responses, combined with single-cell genomics and data science, we craft predictive models of disease biology and drug response.
- Apr 2025Seed$2.4M
#8
Series A · Nijmegen, Gelderland · founded 2011 · 13 employees$65Mraised▾
Developer of antibody-drug-conjugates for cancer treatment. It offers a lead product TGW101 that targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors. It also offersolid-tumor-targeted ADCs as well as radiopharmaceuticals including a HER2-targeted radioimmunotherapeutic.
- Jun 2023Series A$65M
- Mar 2023Grant (prize money)$477.5K
- Mar 2018Grant (prize money)$313.3K
- Jan 2016Grant (prize money)$1.7M
#9
Series C · Nijmegen, Gelderland · founded 2009 · 17 employees$82Mraised▾
Developer of toxin-loaded antibodies for T-cell mediated diseases. Based on the action of conjugated antibodies, it has developed its lead candidate T-Guard, a combination of two toxin-loaded anti-T-cell antibodies that can reset the body's immune system in T-cell mediated diseases, such as Graft-versus-host disease (GVHD).
- Oct 2022Grant (prize money)$2.5M
- Sep 2021Series C$47.4M
- May 2018Series B$30M
- Jun 2012Grant (prize money)$2.4M
#10
Series C · Wageningen, Gelderland · founded 2012 · 17 employees$12.6Mraised▾
Developer of nutritional ingredients with demonstrated health effects. The products include BeniCaros a unique fiber derived from upcycled carrot pomace for the immune system, NL-02 is a crop-derived food ingredient under development to improve gut health, and NL-03 to improve metabolic health.
- Dec 2023Series C$4.9M
- Sep 2020Series B$7.7M
- May 2020Grant (prize money)$55.5K
- Jan 2019Grant (prize money)$304.4K
#11
Series A · Wageningen, Gelderland · founded 2015 · 30 employees$5.9Mraised▾
Developer of DNA-free CRISPR technology for crop resilience and yield improvement. The technology optimizes plant breeding to power and protect future crops. It offers a DNA-free CRISPR method that overcomes traditional limitations. The BioMaas platform allows for multi-trait targeting and scalable automation. Products are completed efficiently once the BioMaas platform has been implemented.
- Apr 2024Series A—
- Aug 2021Series A$5.9M
- Mar 2018Seed—
- Dec 2015Grant (prize money)$54.6K
#12
Late Stage · Zutphen, Gelderland · founded 2000 · 72 employees$48.8Mraised▾
Esperite provides services in the collection, processing, and storage of human adult stem cells, collected from the umbilical cord blood, and the umbilical cord, at birth. It is the largest stem cell bank in Europe.
- Jul 2020Post IPO$41M
- Mar 2018Post IPO$6.4M
- Jan 2018Post IPO$298.6K
- Mar 2017Post IPO$1.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the Netherlands
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 513 Netherlands-affiliated papers.
- Wageningen University & Research116
- Utrecht University59
- Leiden University Medical Center43
- Netherlands Institute of Ecology35
- Erasmus MC30
- Messenger RNA1→6
- Gene3→7
- DNA damage1→5
- Immune system1→5
- DNA repair1→4
- Gene1→5
- Biological pest control1→4
- Population1→4
- Production (economics)1→5
- Public health1→4
- Food security2→4
- Food safety2→4
Where biotechnology is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.